JP2019515035A5 - - Google Patents

Download PDF

Info

Publication number
JP2019515035A5
JP2019515035A5 JP2019508162A JP2019508162A JP2019515035A5 JP 2019515035 A5 JP2019515035 A5 JP 2019515035A5 JP 2019508162 A JP2019508162 A JP 2019508162A JP 2019508162 A JP2019508162 A JP 2019508162A JP 2019515035 A5 JP2019515035 A5 JP 2019515035A5
Authority
JP
Japan
Prior art keywords
cancer
snp
subject
kras
single nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019508162A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019515035A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/029938 external-priority patent/WO2017189906A1/en
Publication of JP2019515035A publication Critical patent/JP2019515035A/ja
Publication of JP2019515035A5 publication Critical patent/JP2019515035A5/ja
Priority to JP2022163987A priority Critical patent/JP2022179694A/ja
Pending legal-status Critical Current

Links

JP2019508162A 2016-04-27 2017-04-27 Ｋｒａｓバリアントがん患者の免疫ベースの処置 Pending JP2019515035A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022163987A JP2022179694A (ja) 2016-04-27 2022-10-12 Ｋｒａｓバリアントがん患者の免疫ベースの処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662328548P 2016-04-27 2016-04-27
US62/328,548 2016-04-27
PCT/US2017/029938 WO2017189906A1 (en) 2016-04-27 2017-04-27 Immune-based treatment of kras-variant cancer patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022163987A Division JP2022179694A (ja) 2016-04-27 2022-10-12 Ｋｒａｓバリアントがん患者の免疫ベースの処置

Publications (2)

Publication Number Publication Date
JP2019515035A JP2019515035A (ja) 2019-06-06
JP2019515035A5 true JP2019515035A5 (enExample) 2020-06-11

Family

ID=59215945

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019508162A Pending JP2019515035A (ja) 2016-04-27 2017-04-27 Ｋｒａｓバリアントがん患者の免疫ベースの処置
JP2022163987A Pending JP2022179694A (ja) 2016-04-27 2022-10-12 Ｋｒａｓバリアントがん患者の免疫ベースの処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022163987A Pending JP2022179694A (ja) 2016-04-27 2022-10-12 Ｋｒａｓバリアントがん患者の免疫ベースの処置

Country Status (5)

Country Link
US (1) US20200325234A1 (enExample)
EP (1) EP3449015A1 (enExample)
JP (2) JP2019515035A (enExample)
CN (1) CN109790581A (enExample)
WO (1) WO2017189906A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7352539B2 (ja) 2017-06-15 2023-09-28 ミラディーエックス 免疫療法に対する腫瘍応答およびその毒性を予測するためのバイオマーカー
WO2019175182A1 (en) * 2018-03-13 2019-09-19 Innate Pharma Treatment of head and neck cancer
WO2020247914A1 (en) * 2019-06-07 2020-12-10 Emory University Kras g12v mutant binds to jak1, inhibitors, pharmaceutical compositions, and methods related thereto

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988617A (en) 1988-03-25 1991-01-29 California Institute Of Technology Method of detecting a nucleotide change in nucleic acids
WO1989010414A1 (en) 1988-04-28 1989-11-02 Robert Bruce Wallace AMPLIFIED SEQUENCE POLYMORPHISMS (ASPs)
US4988167A (en) 1988-08-10 1991-01-29 Fergason James L Light blocking and vision restoration apparatus with glint control
US5118801A (en) 1988-09-30 1992-06-02 The Public Health Research Institute Nucleic acid process containing improved molecular switch
JP3021036B2 (ja) 1989-02-13 2000-03-15 ジェネコ・ピーティーワイ・リミテッド 核酸配列又はその中の変化の検出
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US5302509A (en) 1989-08-14 1994-04-12 Beckman Instruments, Inc. Method for sequencing polynucleotides
US5494810A (en) 1990-05-03 1996-02-27 Cornell Research Foundation, Inc. Thermostable ligase-mediated DNA amplifications system for the detection of genetic disease
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
EP0655090B1 (en) 1992-04-27 2000-12-27 The Trustees Of Dartmouth College Detection of gene sequences in biological fluids
DE69433811T2 (de) 1993-01-07 2005-06-23 Sequenom, Inc., San Diego Dns - sequenzierung durch massenspektronomie
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
IL108159A (en) 1993-12-23 1998-02-08 Orgenics Ltd Apparatus for separation, concentration and detection of target molecules in liquid sample
WO1995021271A1 (en) 1994-02-07 1995-08-10 Molecular Tool, Inc. Ligase/polymerase-mediated genetic bit analysistm of single nucleotide polymorphisms and its use in genetic analysis
US5945283A (en) 1995-12-18 1999-08-31 Washington University Methods and kits for nucleic acid analysis using fluorescence resonance energy transfer
EP2368897B1 (en) 1996-02-09 2016-10-19 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
EP2369007B1 (en) 1996-05-29 2015-07-29 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
US6117635A (en) 1996-07-16 2000-09-12 Intergen Company Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
US5866336A (en) 1996-07-16 1999-02-02 Oncor, Inc. Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
US6506594B1 (en) 1999-03-19 2003-01-14 Cornell Res Foundation Inc Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
WO2008091701A2 (en) * 2007-01-25 2008-07-31 Dana-Farber Cancer Institute Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
EP2527472B1 (en) 2007-05-31 2016-09-28 Yale University A genetic lesion associated with cancer
AU2012203968A1 (en) * 2011-03-21 2012-10-11 Yale University The KRAS variant and tumor biology
AR087405A1 (es) * 2011-08-01 2014-03-19 Genentech Inc Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
CN103547683A (zh) * 2012-03-22 2014-01-29 耶鲁大学 Kras突变和肿瘤生物学
WO2014163684A1 (en) * 2013-04-03 2014-10-09 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2014193937A1 (en) * 2013-05-31 2014-12-04 Yale University The kras variant and response to cancer therapy

Similar Documents

Publication Publication Date Title
Feun et al. Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma
Botticelli et al. The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
Papadatos-Pastos et al. Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors
Duan et al. Genetic biomarkers for hepatocellular carcinoma in the era of precision medicine
WO2019094392A1 (en) Cancer biomarkers and methods of use thereof
US20220160871A1 (en) Methods for photoimmunotherapy and related biomarkers
US20220175787A1 (en) Patient selection for enhancement of anti-tumor immunity in cancer patients
US20240344138A1 (en) Targeted therapies in cancer
JP2017524127A5 (enExample)
TW201900193A (zh) 用於癌症治療之生物標記物
Nakashima et al. Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells
US20220289866A1 (en) Chemically controlled monoclonal antibody target engagement
Fuereder et al. Pembrolizumab plus docetaxel for the treatment of recurrent/metastatic head and neck cancer: A prospective phase I/II study
Church et al. Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma
WO2017205213A1 (en) Combination therapy of abemaciclib and immune checkpoint modulators for use in the treatment of cancer
JP2019515035A5 (enExample)
CA2819080A1 (en) Agtr1 as a marker for bevacizumab combination therapies
Al Bakir et al. Clonal driver neoantigen loss under EGFR TKI and immune selection pressures
WO2018193137A1 (en) Biomarker for small cell lung cancer therapy
Nowak et al. Immune checkpoint inhibitor therapy for malignant pleural mesothelioma
Someya et al. Combined chemoradiotherapy and programmed cell death‐ligand 1 blockade leads to changes in the circulating T‐cell receptor repertoire of patients with non‐small‐cell lung cancer
Liang et al. Pan-cancer analysis for the prognostic and immunological role of CD47: interact with TNFRSF9 inducing CD8+ T cell exhaustion
CA2990299C (en) Method for inducing early t memory response with short peptides anti-tumor vaccine
Palermo et al. Antigen-specificity and DTIC before peptide-vaccination differently shape immune-checkpoint expression pattern, anti-tumor functionality and TCR repertoire in melanoma patients
CN110381953A (zh) 硫化寡糖在制备治疗手术后肝细胞癌病患的药物的用途